Please assess the completion status of the following clinical trial:

Trial Title: Niclosamide Role in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Type 2 diabetes mellitus at least 5 years ago~* Stage 2 and 3 diabetic nephropathy (persistent micro- or macroalbuminuria with urinary albumin creatinine ratio (UACR) \>30mg/g) despite treatment with maximum tolerated dose of ACE inhibitors for at least 8 weeks prior to the screening~* Hemoglobin A1c \> 6.5 % with regular use of insulin and/or oral glucose lowering agents~Exclusion Criteria:~* Type 1 diabetes mellitus~* Severe renal impairment (eGFR\< 30 mL/min/1.73 m2 at screening)~* Pregnant or lactating women~* Chronic heart failure~* Inflammatory or autoimmune disease~* History of kidney disease other than diabetic nephropathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Treatment group (Type: ACTIVE_COMPARATOR): Niclosamide tablets 1 gram once daily
- Control group (Type: PLACEBO_COMPARATOR): Lactose tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).